Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers (opens original article in a new tab)

Boehringer Ingelheim starts three Phase III trials to develop precision oncology treatments for hard-to-treat cancers, focusing on biomarker-informed therapies to improve patient outcomes.

• Boehringer Ingelheim initiates three Phase III trials for hard-to-treat cancers: DAREON®-Lung-1 for small cell lung cancer, DAREON®-NEC-1 for extrapulmonary neuroendocrine carcinoma, and Beamion LUNG-3 for HER2-mutant non-small cell lung cancer.
• The trials focus on biomarker-informed approaches, using obrixtamig and zongertinib to target specific cancer characteristics and improve treatment outcomes.
• Boehringer Ingelheim aims to advance precision oncology by developing targeted therapies for aggressive cancers with limited treatment options.